ArticleJournal of cellular biochemistry2020
Long noncoding RNA BHLHE40-AS1 promotes early breast cancer progression through modulating IL-6/STAT3 signaling.
Article in Journal of cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Genome-wide association study provides novel insight into the genetic architecture of severe obesity.PLoS genetics · 2025Pooled it
- Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women.Breast cancer research : BCR · 2026Article
- BRRIAR lncRNA alters breast cancer risk by modulating interferon signaling in cis and in trans.Molecular cancer · 2026Article
- The Role of M6A LncRNA Modification in Papillary Thyroid Cancer.International journal of molecular sciences · 2025Review
- Identification and Copy Number Variant Analysis of Enhancer Regions of Genes Causing Spinocerebellar Ataxia.International journal of molecular sciences · 2024Article
- The regulatory relationship between transcription factor STAT3 and noncoding RNA.Cellular & molecular biology letters · 2024Review
- Identification of a transcription factor network regulating anti-TNF mediatedDiscovery immunology · 2024Article
- The programmed death ligand 1 interactome demonstrates bidirectional signaling coordinating immune suppression and cancer progression in head and neck squamous cell carcinoma.Journal of the National Cancer Institute · 2023Article
- Differential expression profiles and functional analysis of long non-coding RNAs in calcific aortic valve disease.BMC cardiovascular disorders · 2023Article
- Epigenetic Alterations in DCIS Progression: What Can lncRNAs Teach Us?International journal of molecular sciences · 2023Review
- LINC00426 is a potential immune phenotype-related biomarker and an overall survival predictor in PAM50 luminal B breast cancer.Frontiers in genetics · 2023Article
- The current advances of lncRNAs in breast cancer immunobiology research.Frontiers in immunology · 2023Review
- Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers.Communications biology · 2022Article
- Article
- Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance.Frontiers in genetics · 2022Review
- RING-Finger Protein 6 promotes Drug Resistance in RetinoblastomaPathology oncology research : POR · 2022Article
- Genome-wide association and functional interrogation identified a variant at 3p26.1 modulating ovarian cancer survival among Chinese women.Cell discovery · 2021Article
- Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.Breast cancer research : BCR · 2021Article
- Article
- A Five Immune-Related lncRNA Signature as a Prognostic Target for Glioblastoma.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Ductal carcinoma in situ (DCIS) is a nonobligate precursor to invasive breast cancer. Only a small percentage of DCIS cases are predicted to progress; however, there is no method to determine which DCIS lesions will remain innocuous from those that will become invasive disease. Therefore, DCIS is treated aggressively creating a current state of overdiagnosis and overtreatment. There is a critical need to identify functional determinants of progression of DCIS to invasive ductal carcinoma (IDC). Interrogating biopsies from five patients with contiguous DCIS and IDC lesions, we have shown that expression of the long noncoding RNA BHLHE40-AS1 increases with disease progression. BHLHE40-AS1 expression supports DCIS cell proliferation, motility, and invasive potential. Mechanistically, BHLHE40-AS1 modulates interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3) activity and a proinflammatory cytokine signature, in part through interaction with interleukin enhancer-binding factor 3. These data suggest that BHLHE40-AS1 supports early breast cancer progression by engaging STAT3 signaling, creating an immune-permissive microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.